Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 5/2002

01-11-2002 | Original Article

Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial

Authors: Yun Yen, Warren Chow, Lucille Leong, Kim Margolin, Robert Morgan, James Raschko, Stephen Shibata, George Somlo, Przemyslaw Twardowski, Paul Frankel, Jeff Longmate, Timothy Synold, Edward M. Newman, Heinz-Josef Lenz, David Gandara, James H. Doroshow

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2002

Login to get access
Metadata
Title
Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial
Authors
Yun Yen
Warren Chow
Lucille Leong
Kim Margolin
Robert Morgan
James Raschko
Stephen Shibata
George Somlo
Przemyslaw Twardowski
Paul Frankel
Jeff Longmate
Timothy Synold
Edward M. Newman
Heinz-Josef Lenz
David Gandara
James H. Doroshow
Publication date
01-11-2002
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/2002
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-002-0492-9

Other articles of this Issue 5/2002

Cancer Chemotherapy and Pharmacology 5/2002 Go to the issue

Original article

A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia

Original Article

Toxicity of intracranial and intraperitoneal O6-benzyl guanine in combination with BCNU delivered locally in a mouse model

Original Article

Angiostatin potentiates cyclophosphamide treatment of metastatic disease

Short Communication

Carboplatin hypersensitivity presenting as coronary vasospasm – a case report

Original Article

Tumour cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells

Original article

The effect of malignant effusions on methotrexate disposition
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits